Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tripartite motif-containing protein 28 (TRIM28), also known as KRAB-associated protein 1 (KAP1) or transcription intermediary factor 1-beta (TIF1-beta), is a multifunctional nuclear corepressor and chromatin regulator that interacts with the KRAB domain of zinc finger transcription factors to drive transcriptional silencing and heterochromatin formation[1][2]. TRIM28's structure includes a tripartite motif (RING finger, B-boxes, coiled-coil) characteristic of the TRIM family, as well as domains for interaction with heterochromatin protein 1 (HP1) and a bromodomain which recognizes acetylated lysine residues[2]. It plays critical roles in epigenetic silencing of endogenous retroviral elements, maintenance of genome integrity (notably in DNA double-strand break repair), and regulation of 3D chromatin architecture, notably in T cell activation and differentiation[3]. TRIM28 is essential for embryonic development and regulates genes involved in cell proliferation, survival, and immune responses such as suppression of viral gene expression. Aberrations in TRIM28 function or expression are linked to cancer progression, neurodegenerative disorders, viral infections, inflammation, and metabolism-related diseases[1][2][3][4]. As a consequence, it is an important, though challenging, candidate for therapeutic targeting in oncology, immunology, and virology.
No approved drugs directly target TRIM28, so this entry is currently null. Mechanistically, potential future agents might block corepressor functions, modulate SUMOylation/E3 ligase activity, or disrupt protein–protein interactions relevant to chromatin remodeling or retroelement silencing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tripartite motif-containing protein 28 (TRIM28).